These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8726028)

  • 1. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
    Ford CW; Hamel JC; Wilson DM; Moerman JK; Stapert D; Yancey RJ; Hutchinson DK; Barbachyn MR; Brickner SJ
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1508-13. PubMed ID: 8726028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
    Zurenko GE; Yagi BH; Schaadt RD; Allison JW; Kilburn JO; Glickman SE; Hutchinson DK; Barbachyn MR; Brickner SJ
    Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y; Sunagawa M
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT; Zurenko GE
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1902-6. PubMed ID: 12760865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
    Schülin T; Thauvin-Eliopoulos C; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2873-6. PubMed ID: 10582874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Steckelberg JM
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
    Chien JW; Kucia ML; Salata RA
    Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
    Louie A; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
    Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
    Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
    Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
    Jeong JW; Jung SJ; Lee HH; Kim YZ; Park TK; Cho YL; Chae SE; Baek SY; Woo SH; Lee HS; Kwak JH
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5359-62. PubMed ID: 20855730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
    Schaadt RD; Batts DH; Daley-Yates PT; Pawsey SD; Stalker DJ; Zurenko GE
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):201-4. PubMed ID: 9327249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
    Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
    J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.